SERACARE Life Sciences has launched five new infectious disease panels, including the first for parvovirus B19 which is associated with fifth disease. The other new products include panels for human immunodeficiency virus (HIV), hepatitus A (HAV), hepatitus B (HBV), and cytomegalovirus (CMV).
The Parvovirus B19 panel (PVP201) contains 21 samples characterised for multiple IgM and IgG assays as well as B19 DNA, a marker used to screen plasma collected for fractionation.
The HIV panel (PRD201) provides a diverse set of samples, geographically and genotypically. Eight of the nine panel members are HIV positive, representing eight different HIV-1 genotypes from seven countries. This panel is designed to help researchers, manufacturers, and laboratories develop, evaluate, and troubleshoot HIV assays, including those for HIV RNA and tests for combined HIV antigen and antibody.
The worldwide HBV DNA panel (WWHD301) includes samples from ten countries with HBV genotypes ranging from A through H. A broad range of data is available for this panel, with information on genotype, drug resistance mutations, and test results for, HBV DNA, HBsAg, and HBeAg.
Anti-Hepatitis A panel (PHT202) includes members positive for IgG and IgM, with specimens collected from 2000 to 2010, and represents a diverse range of HAV reactivities from low to high. Data are available for both new and established test methods, providing greater applicability across a broad range of laboratory and research settings.
The Anti-CMV panel (PTC203) provides 21 naturally occurring panel members with data from 12 commercially available anti-CMV assays.
These new infectious disease panels are available immediately worldwide from SeraCare.